Cypress Capital, LLC Gilead Sciences, Inc. Transaction History

Cypress Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 22, 2024	BUY	$63.15 - $72.88 $820 - $947	13 New	13 $0
Q1 2022 May 09, 2022	SELL	$57.92 - $72.58 $175,497 - $219,917	-3,030 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$64.88 - $73.64 $11,678 - $13,255	-180 Reduced 5.61%	3,030 $220,000
Q3 2021 Feb 10, 2022	BUY	$67.69 - $73.03 $217,081 - $234,207	3,207 Added 106900.0%	3,210 $224,000
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $180 - $205	3 New	3 $0
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $1.4 Million - $1.76 Million	-22,595 Closed	0 $0
Q2 2020 Aug 20, 2020	BUY	$72.34 - $84.0 $101,565 - $117,936	1,404 Added 6.63%	22,595 $1.74 Million
Q4 2019 Feb 10, 2020	BUY	$61.62 - $67.78 $5,669 - $6,235	92 Added 0.44%	21,191 $1.38 Million
Q3 2019 Nov 21, 2019	SELL	$62.51 - $69.0 $3,188 - $3,519	-51 Reduced 0.24%	21,099 $1.34 Million
Q2 2019 Jul 11, 2019	SELL	$61.87 - $69.38 $60,880 - $68,269	-984 Reduced 4.45%	21,150 $1.43 Million
Q1 2019 May 01, 2019	BUY	$62.53 - $70.05 $56,902 - $63,745	910 Added 4.29%	22,134 $1.44 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $1.28 Million - $1.68 Million	21,224 New	21,224 $1.33 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Cypress Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Cypress Capital, LLC with notifications on news.